Mesoblast Limited (ASX:MSB – Get Free Report) insider Gregory George bought 74,621 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was purchased at an average price of A$12.88 ($8.20) per share, with a total value of A$961,118.48 ($612,177.38).
Gregory George also recently made the following trade(s):
- On Monday, March 3rd, Gregory George purchased 5,034,129 shares of Mesoblast stock. The shares were acquired at an average price of A$2.95 ($1.88) per share, for a total transaction of A$14,830,544.03 ($9,446,206.39).
Mesoblast Price Performance
The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -23.29, a P/E/G ratio of 9.56 and a beta of 2.38. The company has a debt-to-equity ratio of 24.76, a quick ratio of 1.82 and a current ratio of 1.18.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
- Five stocks we like better than Mesoblast
- What Investors Need to Know to Beat the Market
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Must-Own Stocks to Build Wealth This Decade
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
